March 22, 2006 -- Sanofi-Aventis and Bristol-Myers Squibb moved sharply higher after settling a patent suit over Plavix, the $6.2 billion blockbuster blood thinning drug; Nabi Biopharma jumped after announcing it would resume development of StaphVax, a product that failed a Phase III trial; Cephalon traded in a wide range on worries that Sparlon, its treatment for ADHD, might get a black box warning; the FDA put off for 3 months a decision on Tysabri, the multiple sclerosis drug from Biogen Idec/Elan; Neurobiological Technologies began its second Phase III trial of stroke drug Viprinix; and a non-Hodgkin’s lymphoma from Cell Therapeutics was effective in early tests. The Centient Biotech 200™ was 18.5 points higher at 4019.14, an increase of .46%. More details...
